BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 3795531)

  • 21. Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients.
    Strenger V; Kerbl R; Dornbusch HJ; Ladenstein R; Ambros PF; Ambros IM; Urban C
    Pediatr Blood Cancer; 2007 May; 48(5):504-9. PubMed ID: 16732582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mass screening of neuroblastoma in Sapporo City, Japan.
    Nishi M; Miyake H; Takeda T; Kikuchi Y; Hanai J; Yonemori H; Takasugi N
    Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):327-31. PubMed ID: 1456398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of a rapid and reliable method for mass screening for neuroblastoma in infants.
    Schilling FH; Oberrauch W; Schanz F; Treuner J
    Prog Clin Biol Res; 1991; 366():579-83. PubMed ID: 2068176
    [No Abstract]   [Full Text] [Related]  

  • 24. Urinary homovanillic and vanillylmandelic acid in the diagnosis of neuroblastoma: report from the Italian Cooperative Group for Neuroblastoma.
    Barco S; Gennai I; Reggiardo G; Galleni B; Barbagallo L; Maffia A; Viscardi E; De Leonardis F; Cecinati V; Sorrentino S; Garaventa A; Conte M; Cangemi G
    Clin Biochem; 2014 Jun; 47(9):848-52. PubMed ID: 24769278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interchangeability between 24-hour collection and single spot urines for vanillylmandelic and homovanillic acid levels in the diagnosis of neuroblastoma.
    Cangemi G; Barco S; Reggiardo G; Viscardi E; Di Cataldo A; Garaventa A; Melioli G; Conte M
    Pediatr Blood Cancer; 2013 Dec; 60(12):E170-2. PubMed ID: 23813598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Sensitivity and specificity of the determination of urinary catecholamines and their acid metabolites in the diagnosis of neuroblastoma in children].
    Horsmans Y; Desager JP; Harvengt C
    Bull Cancer; 1990; 77(10):985-9. PubMed ID: 2249018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluctuation in the concentrations of vanillylmandelic acid and homovanillic acid in mass screening for neuroblastoma.
    Nishi M; Miyake H; Takeda T; Yamashiro K; Takasugi N; Hanai J; Kawai T
    Eur J Pediatr; 1990 Sep; 149(12):859-61. PubMed ID: 2226572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determination of urinary vanillylmandelic acid and homovanillic acid by high performance liquid chromatography for mass screening of neuroblastoma.
    Sato Y; Hanai J; Takasugi N; Takeda T
    Tohoku J Exp Med; 1986 Oct; 150(2):169-74. PubMed ID: 3810642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feasibility of chemical screening of urine for neuroblastoma case finding in infancy in Quebec.
    Scriver CR; Gregory D; Bernstein M; Clow CL; Weisdorf T; Dougherty GE; Auray-Blais C; Giguère R; Lemieux B; Laberge C
    CMAJ; 1987 May; 136(9):952-6. PubMed ID: 3105859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of the diurnal variations in urinary homovanillic and vanillylmandelic acid excretion for the diagnosis and follow-up of patients with neuroblastoma.
    Tuchman M; Robison LL; Maynard RC; Ramnaraine ML; Krivit W
    Clin Biochem; 1985 Jun; 18(3):176-9. PubMed ID: 4039636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Past and future of neuroblastoma screening in Japan.
    Sawada T
    Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):320-6. PubMed ID: 1456397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Vanillylmandelic acid (VMA) and homovanillic acid (HVA)].
    Kanesaka Y; Tomita K
    Nihon Rinsho; 1999 Dec; 57 Suppl():223-5. PubMed ID: 10778106
    [No Abstract]   [Full Text] [Related]  

  • 33. Results of mass screening for neuroblastoma in Sapporo, Japan.
    Takeda T; Nishi M; Shimada M; Nakadate H; Hatae Y; Naito H; Hanai J; Kawai T; Takasugi N
    Prog Clin Biol Res; 1991; 366():595-601. PubMed ID: 2068178
    [No Abstract]   [Full Text] [Related]  

  • 34. False positive results in a neuroblastoma screening programme.
    Bell S; Parker L; Craft AW; Dale G; McGill AC; Seviour J; Cole M; Smith J
    Med Pediatr Oncol; 1994; 22(3):181-6. PubMed ID: 8272007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroblastoma: the case for screening infants in North America.
    Woods WG; Tuchman M
    Pediatrics; 1987 Jun; 79(6):869-73. PubMed ID: 3588142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitation of Neuroblastoma Markers Homovanillic Acid (HVA) and Vanillylmandelic Acid (VMA) in Urine by Gas Chromatography-Mass Spectrometry (GC/MS).
    Beals M; Ramoo B; Clinton Frazee C; Garg U
    Methods Mol Biol; 2022; 2546():185-194. PubMed ID: 36127589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Early neuroblastoma detection in Germany. On the status of the Hamburg-Stuttgart cooperative pilot study].
    Schilling FH; Erttmann R; Dohrmann S; Erb N; Winkler K; Gross U; Treuner J
    Klin Padiatr; 1992; 204(4):282-7. PubMed ID: 1518266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased urinary HVA levels in neuroblastoma screens related to diet, not tumor.
    Numata K; Kusui H; Kawakatsu H; Kizaki Z; Sawada T
    Pediatr Hematol Oncol; 1997; 14(6):569-76. PubMed ID: 9383810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urinary excretion of catechol metabolites particularly MHPG in children. Relation to age, body mass indices and thyroid function.
    Popa M; Stefănescu AM; Dumitriu L
    Endocrinologie; 1986; 24(3):203-14. PubMed ID: 3775226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Initial urinary catecholamine metabolite concentrations and prognosis in neuroblastoma.
    Laug WE; Siegel SE; Shaw KN; Landing B; Baptista J; Gutenstein M
    Pediatrics; 1978 Jul; 62(1):77-83. PubMed ID: 683787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.